We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
EKF Diagnostics Holdings PLC | AQSE:EKF.GB | Aquis Stock Exchange | Ordinary Share | GB0031509804 | Ordinary Shares 1p |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.50 | 20.00 | 31.00 | 27.50 | 25.00 | 27.50 | 0.00 | 16:29:52 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMEKF
RNS Number : 5081E
EKF Diagnostics Holdings PLC
18 July 2016
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Notification of transactions by Persons Discharging Managerial Responsibilities and persons closely associated with them
EKF Diagnostics Holdings plc (AIM: EKF) announces that on 18 July 2016, the Company was notified that Harwood Capital LLP ("Harwood") acquired 9,000,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") as investment manager to North Atlantic Smaller Companies Investment Trust PLC ("NAIT"). Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood and a director and shareholder in NAIT.
Following the above transaction, which was completed on 15 July 2016 at a price of 14.89 pence per share, NAIT's interest is now in 87,100,000 Ordinary Shares, representing 18.76% of the Company's issued share capital. The interests of Oryx International Growth Fund Limited ("Oryx", whose investment adviser is Harwood) remains as previously disclosed in 40,000,000 Ordinary Shares, representing 8.62% of the Company's issued share capital. Mr Mills is also a director and shareholder in Oryx.
The total indirect beneficial interest of Mr Mills is, following the above transaction, therefore now in 127,100,000 Ordinary Shares, representing 27.38% of the Company's issued share capital.
EKF Diagnostics Holdings plc Tel: 029 2071 0570 Julian Baines, CEO Richard Evans, FD & COO Panmure Gordon (UK) Limited Tel: 020 7886 2500 Paul Fincham Peter Steel Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com Paul McManus Mob: 07980 541 893 Lianne Cawthorne Mob: 07584 391 303
This notification is made in accordance with the requirements of the EU Market Abuse Regulation. Further details:
Initial notification / amendment: Initial
Ordinary Shares Identification Code: ISIN GB0031509804
Aggregated information: N/A
Place of the transaction: London Stock Exchange, AIM (XLON)
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBUGDRUGBBGLI
(END) Dow Jones Newswires
July 18, 2016 11:06 ET (15:06 GMT)
1 Year EKF Diagnostics Chart |
1 Month EKF Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions